Analyst firms · Robert W. Baird · AMLX
Robert W. Baird AMLX price target and rating history
Amylyx Pharmaceuticals Inc. (AMLX) · Health Care
Robert W. Baird rates Amylyx Pharmaceuticals Inc. (AMLX) Outperform with a $11 price target, as of its latest action on Nov 18, 2024. It has published 3 rating actions on AMLX since January 2024, including 1 upgrade and 1 downgrade.
- Current rating
- Outperform
- Price target
- $11
- Median target, all firms
- Too few
- Actions on AMLX
- 3
Robert W. Baird price target on AMLX
Every Robert W. Baird rating on AMLX
- Nov 18, 2024
- Mar 11, 2024
- Jan 3, 2024
Questions about Robert W. Baird and AMLX
- What is Robert W. Baird's price target for AMLX?
- Robert W. Baird's latest stated price target for Amylyx Pharmaceuticals Inc. (AMLX) is $11, from its action on Nov 18, 2024.
- What is Robert W. Baird's rating on AMLX?
- Robert W. Baird rates AMLX Outperform, a bullish rating, as of Nov 18, 2024.
- When did Robert W. Baird last change its view on AMLX?
- On Nov 18, 2024, Robert W. Baird upgrades to Outperform from Neutral, price target $3 to $11.
More AMLX rating histories
All Robert W. Baird ratingsAMLX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.